News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Intellikine, Inc. Earns $4 Million in Milestone Payments for Initiation of Two Phase 1 Clinical Trials for IPI-145, a Potent Inhibitor of PI3Kdelta and PI3Kgamma



10/31/2011 8:38:28 AM

LA JOLLA, Calif.--(BUSINESS WIRE)--Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145. Intellikine licensed development and commercialization rights for IPI-145, a potent, orally available inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma, to Infinity Pharmaceuticals, Inc. in July 2010.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES